Vectorite Biomedical

Vectorite Biomedical EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vectorite Biomedical (4170.TWO) as of Nov 5, 2026 is -21.91 M TWD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was -25.97 M TWD — a change of -15.65% (higher).

EBITDA

-21.91 MTWD

YoY

-15.65%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vectorite Biomedical is 2025 -21.91 M TWD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vectorite Biomedical was 2024 -25.97 M TWD. It decreases by -15.65% higher compared to the previous year.

The Vectorite Biomedical EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-66.01 M TWD
Jan 1, 2019
-90.26 M TWD
Jan 1, 2020
-51.63 M TWD
Jan 1, 2021
-34.81 M TWD
Jan 1, 2022
30.54 M TWD
Jan 1, 2023
-16.13 M TWD
Jan 1, 2024
-25.97 M TWD
Jan 1, 2025
-21.91 M TWD
The Vectorite Biomedical EBITDA history
YEAREBITDAYoY
-21.91 MTWD-15.65%
-25.97 MTWD+61.00%
-16.13 MTWD-152.83%
30.54 MTWD-187.73%
-34.81 MTWD-32.58%
-51.63 MTWD-42.80%
-90.26 MTWD+36.73%
-66.01 MTWD+21.57%
-54.30 MTWD-21.14%
-68.86 MTWD-8.73%
-75.44 MTWD+124.61%
-33.59 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Vectorite Biomedical Stock analysis

What does Vectorite Biomedical do? Xinpin Biomedical Co., Ltd. established Xinpin Biomedical Group with the concept of “preventing problems before it happens” and is headquartered in Taipei, New Taipei. The firm offers a range of services including immune cell collection, processing and storage, cell preparation safety testing, anti-cancer immunity testing, original design manufacturer or contract development and manufacturing organization services, related medical consulting, and laboratory quality management. Its product portfolio features dendritic cell vaccines and natural killer cell preparations designed for cancer treatment. Products are mainly sold domestically. Vectorite Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Vectorite Biomedical stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vectorite Biomedical is -21.91 M TWD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Vectorite Biomedical changed from -25.97 M TWD to -21.91 M TWD, representing a -15.65% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Vectorite Biomedical since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Vectorite Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — Vectorite Biomedical

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — Vectorite Biomedical